Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Changes in thymidine kinase, thymidylate synthase, and standardized uptake values
研究概览
简要总结
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
详细描述
OBJECTIVES:
Primary
- Evaluate the use of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography (PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine kinase levels) in patients with cancer.
Secondary
- Determine the efficacy of FLT PET imaging in detecting lesions and estimating response to treatment.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Meets one of the following criteria:
- •Histologically confirmed solid tumor or hematologic malignancy
- •Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging
- •PATIENT CHARACTERISTICS:
- •Able to lie still in the PET scanner
- •Girth and weight must be suitable to enter the gantry
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •PRIOR CONCURRENT THERAPY:
- •Not specified
排除标准
- 未提供
研究组 & 干预措施
3'-deoxy-3'-[18F]fluorothymidine
The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
干预措施: 3'-deoxy-3'-[18F]fluorothymidine (Device)
结局指标
主要结局
Changes in thymidine kinase, thymidylate synthase, and standardized uptake values
时间窗: before and after therapy
Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs
时间窗: at time of PET or CT PET Scan
次要结局
- FLT PET response rate(up to 2 hours during PET scan)
研究者
Anthony F. Shields, MD PhD
Principal Investigator
Barbara Ann Karmanos Cancer Institute